These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 36972454)
1. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454 [TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance. Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z Front Immunol; 2018; 9():2359. PubMed ID: 30369931 [TBL] [Abstract][Full Text] [Related]
3. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q Front Immunol; 2021; 12():686439. PubMed ID: 34616392 [TBL] [Abstract][Full Text] [Related]
4. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction. Lamarthée B; Marchal A; Charbonnier S; Blein T; Leon J; Martin E; Rabaux L; Vogt K; Titeux M; Delville M; Vinçon H; Six E; Pallet N; Michonneau D; Anglicheau D; Legendre C; Taupin JL; Nemazanyy I; Sawitzki B; Latour S; Cavazzana M; André I; Zuber J Nat Commun; 2021 Nov; 12(1):6446. PubMed ID: 34750385 [TBL] [Abstract][Full Text] [Related]
5. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Dawson NAJ; Rosado-Sánchez I; Novakovsky GE; Fung VCW; Huang Q; McIver E; Sun G; Gillies J; Speck M; Orban PC; Mojibian M; Levings MK Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32817364 [TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. Tenspolde M; Zimmermann K; Weber LC; Hapke M; Lieber M; Dywicki J; Frenzel A; Hust M; Galla M; Buitrago-Molina LE; Manns MP; Jaeckel E; Hardtke-Wolenski M J Autoimmun; 2019 Sep; 103():102289. PubMed ID: 31176558 [TBL] [Abstract][Full Text] [Related]
7. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042 [TBL] [Abstract][Full Text] [Related]
8. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice. Bézie S; Charreau B; Vimond N; Lasselin J; Gérard N; Nerrière-Daguin V; Bellier-Waast F; Duteille F; Anegon I; Guillonneau C Blood Adv; 2019 Nov; 3(22):3522-3538. PubMed ID: 31730699 [TBL] [Abstract][Full Text] [Related]
10. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. Mohseni YR; Tung SL; Dudreuilh C; Lechler RI; Fruhwirth GO; Lombardi G Front Immunol; 2020; 11():1608. PubMed ID: 32793236 [TBL] [Abstract][Full Text] [Related]
12. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application. Henschel P; Landwehr-Kenzel S; Engels N; Schienke A; Kremer J; Riet T; Redel N; Iordanidis K; Saetzler V; John K; Heider M; Hardtke-Wolenski M; Wedemeyer H; Jaeckel E; Noyan F J Autoimmun; 2023 Jul; 138():103057. PubMed ID: 37224732 [TBL] [Abstract][Full Text] [Related]
13. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD. Imura Y; Ando M; Kondo T; Ito M; Yoshimura A JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32525846 [TBL] [Abstract][Full Text] [Related]
14. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it. Yin X; He L; Guo Z Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414 [TBL] [Abstract][Full Text] [Related]
15. Building a CAR-Treg: Going from the basic to the luxury model. Rosado-Sánchez I; Levings MK Cell Immunol; 2020 Dec; 358():104220. PubMed ID: 33096321 [TBL] [Abstract][Full Text] [Related]
16. Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T Front Immunol; 2022; 13():770132. PubMed ID: 35154098 [TBL] [Abstract][Full Text] [Related]
17. Exhaustion of CAR T cells: potential causes and solutions. Kouro T; Himuro H; Sasada T J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821 [TBL] [Abstract][Full Text] [Related]
18. CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from Nowak A; Lock D; Bacher P; Hohnstein T; Vogt K; Gottfreund J; Giehr P; Polansky JK; Sawitzki B; Kaiser A; Walter J; Scheffold A Front Immunol; 2018; 9():199. PubMed ID: 29467769 [TBL] [Abstract][Full Text] [Related]